This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The discussion delves into considerations regarding the concentration, citrate-free nature, and volume of adalimumab, particularly in the context of transitioning patients to biosimilars. The speaker emphasizes the importance of minimizing patient discomfort by opting for agents with smaller syringes, no citrate, and lower volume. They highlight the popularity of citrate-free products due to reduced pain and mentions that high concentration with citrate may cause less injection site discomfort. Ideally, biosimilars should offer high concentration, small needles, and be citrate-free, although not all currently meet these criteria. Various delivery mechanisms impact patient experience, necessitating education and informed choices.

The speaker adds insights from a dermatological perspective, noting patient preferences for specific pen devices and potential implications for treatment adherence. He suggests tracking patient feedback to inform future decisions. Concerns about off-label doses and the burden of multiple devices underscore the need for streamlined options to facilitate adherence.

The complexity of managing multiple devices and formulations requires extensive patient and staff education. Providers must navigate diverse product landscapes to ensure optimal treatment experiences. The discussion underscores the need for comprehensive understanding and support to facilitate informed decision-making and improve patient outcomes.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.